Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
de Lazzari E, Lonca M, Rojas J, Gonzalez-Cordon A, Blanch J, Inciarte A, Tricas A, Rodriguez A, Martinez-Rebollar M, Laguno M, Mallolas J, Sanchez-Palomino S, Plana M, Blanco JL, Martinez E. de Lazzari E, et al. Among authors: lonca m. AIDS. 2019 Oct 1;33(12):1891-1896. doi: 10.1097/QAD.0000000000002311. AIDS. 2019. PMID: 31335805 Clinical Trial.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Laguno M, et al. Among authors: lonca m. AIDS. 2004 Sep 3;18(13):F27-36. doi: 10.1097/00002030-200409030-00003. AIDS. 2004. PMID: 15316335 Clinical Trial.
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martínez-Rebollar M, et al. Among authors: lonca m. Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef. Ther Drug Monit. 2013. PMID: 23851911
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.
Blanco JL, Gonzalez-Cordón A, Llibre JM, Calvo M, Gutierrez F, Podzamczer D, Laguno M, Fumero E, Murillas J, Mallolas J, Martinez-Rebollar M, Lonca M, Perez I, Gatell JM, Martinez E. Blanco JL, et al. Among authors: lonca m. Antivir Ther. 2015;20(5):487-92. doi: 10.3851/IMP2812. Epub 2014 Jun 25. Antivir Ther. 2015. PMID: 24964358 Clinical Trial.
64 results